Home / Associations between PSA kinetics and cause-specific mortality in patients with localised prostate cancer managed observationally: A sub-group analysis of the SPCG-6 study
Publication: European Urology Supplements, Volume 2, Issue 14
© 2015 European Association of Urology, Published by Elsevier B.V.
Men with non-metastatic prostate cancer randomized to placebo in the SPCG-6 trial had a higher risk of dying of non-PCA related disease (38%) compared to PCA related mortality (31%) at 15 years. Early PSA kinetics after randomization were only useful to predict survival in men with PSA between 10-25ng/ml. The risk of dying of prostate cancer almost doubled when initial PSADT was <3 years (42%) as compared >3 years (25%). Interestingly, in men with higher PSA values at baseline, kinetics had little predictive value for survival.